Discovery of ABBV-4083, a novel analog of tylosin a that has potent anti-wolbachia and anti-filarial activity

31Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

There is a significant need for improved treatments for onchocerciasis and lymphatic filariasis, diseases caused by filarial worm infection. In particular, an agent able to selectively kill adult worms (macrofilaricide) would be expected to substantially augment the benefits of mass drug administration (MDA) with current microfilaricides, and to provide a solution to treatment of onchocerciasis / loiasis co-infection, where MDA is restricted. We have identified a novel macrofilaricidal agent, Tylosin A (TylA), which acts by targeting the worm-symbiont Wolbachia bacterium. Chemical modification of TylA leads to improvements in anti-Wolbachia activity and oral pharmacokinetic properties; an optimized analog (ABBV-4083) has been selected for clinical evaluation.

Cite

CITATION STYLE

APA

von Geldern, T. W., Morton, H. E., Clark, R. F., Brown, B. S., Johnston, K. L., Ford, L., … Kempf, D. J. (2019). Discovery of ABBV-4083, a novel analog of tylosin a that has potent anti-wolbachia and anti-filarial activity. PLoS Neglected Tropical Diseases, 13(2). https://doi.org/10.1371/journal.pntd.0007159

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free